For broader context on peptide mechanisms and research applications, explore our Research Library.
Most peptides are studied for what they do to the body. A new 2026 study out of the University of Copenhagen went a level deeper, asking what MOTS-c does inside the mitochondria themselves. Published in Free Radical Biology and Medicine, it’s one of the more mechanistically detailed MOTS-c studies to date, and it produced findings that both confirm existing theory and complicate a widely held assumption.
MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino acid peptide encoded not by nuclear DNA, but by mitochondrial DNA itself. It functions as a signaling molecule, rising naturally during exercise and declining with age. Prior research has documented its effects on whole-body metabolism — insulin sensitivity, glucose uptake, fat oxidation. What hadn’t been examined closely until now is whether MOTS-c directly improves mitochondrial function at the intrinsic level, independent of those systemic effects.
The Copenhagen team used two distinct transgenic mouse strains alongside a human exercise trial to isolate this question. The results showed that MOTS-c administration enhanced mitochondrial bioenergetic performance — meaning mitochondria produced energy more efficiently, while simultaneously reducing reactive oxygen species (ROS) emission and ROS-related protein damage. What’s notable is that these improvements occurred without any measurable increase in mitochondrial respiratory protein content. That points to qualitative changes in how existing mitochondria operate, not simply an increase in mitochondrial volume. The effects were found to run through both PGC-1α, the master regulator of mitochondrial biogenesis, and AMPK, the cellular energy sensor activated by exercise and caloric restriction.
The human component of the study produced the most thought-provoking result. It has long been assumed that skeletal muscle is the primary source of MOTS-c circulating in the bloodstream during exercise. The researchers tested this directly using arterio-venous difference measurements during one-legged knee extensor exercise and found no evidence to support it. Interstitial MOTS-c levels in muscle rose during exercise, but that increase wasn’t reflected in the blood the way it would be if muscle were the source. Where circulating MOTS-c actually originates, possibly the liver, possibly other tissues, remains an open question.
As of 2026, MOTS-c remains classified as a research compound. The evidence base from preclinical models and human trials is growing, but large-scale randomized controlled trials are still needed to establish a definitive protocol.